CD19 and cancer: In a public pan‐cancer B cell dataset [16], IREB2 was enriched in memory and cycling B cells, positively associated with (Figure 6I,J), positively associated with functional/prognostic markers (CD19, CD80, CD86, FCRL4, FAS), and negatively with poor‐prognosis genes (IGHG1, IGHA1, CD27), consistent across lung cancer subsets (Figure 6I–O).